Biocon recalls 3,665 bottles of antifungal drug in U.S. for failed degradation specifications

The lot has been manufactured by Biocon Pharma and distributed in the U.S. by Iselin-based Biocon Pharma Inc.

Updated - February 19, 2023 12:33 pm IST - New Delhi

As per the U.S. FDA, a class II recall is initiated in a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.

As per the U.S. FDA, a class II recall is initiated in a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.

Biotechnology major Biocon is recalling 3,665 bottles of antifungal medication in the U.S. market for “failed degradation specifications”, according to the U.S. Food and Drug Administration (USFDA).

In its latest Enforcement Report, the U.S. health regulator said that the Bengaluru-based firm is recalling 3,665 bottles of Posaconazole Delayed-Release Tablets (100 mg, 60-count bottle), used to treat serious fungal infections like invasive aspergillosis.

The U.S. FDA noted that the New Jersey-based Biocon Pharma Inc. is recalling the affected lot due to “Failed Impurities/Degradation Specifications: High Out Of Specification degradation results.”

The lot has been manufactured by Biocon Pharma and distributed in the U.S. by Iselin-based Biocon Pharma Inc., it added.

Biocon initiated the Class II nationwide (U.S.) recall on January 31, this year.

As per the U.S. FDA, a class II recall is initiated in a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.

On February 12, Biocon stated that the U.S. FDA has issued a Complete Response Letter (CRL) for the biologics licence application filed for Bevacizumab by its partner Viatris.

The U.S. FDA issues a CRL to convey to a company that its initial review of an application is complete and it cannot approve the application in its present form.

Earlier on January 7, the company had stated that the U.S. FDA has issued a complete response letter for Biocon Biologics' application for Insulin-R, a proposed biosimilar for diabetes treatment.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.